Edition:
India

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

6.28EUR
23 Oct 2020
Change (% chg)

€0.12 (+1.95%)
Prev Close
€6.16
Open
€6.15
Day's High
€6.37
Day's Low
€6.15
Volume
247,120
Avg. Vol
500,415
52-wk High
€7.35
52-wk Low
€1.78

Latest Key Developments (Source: Significant Developments)

Valneva Announces Retirement Of CFO
Friday, 18 Sep 2020 

Sept 18 (Reuters) - Valneva SE ::REG-VALNEVA ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER DAVID LAWRENCE.COMPANY HAS INITIATED A SEARCH PROCESS WITH A LEADING GLOBAL RECRUITMENT AGENCY TO IDENTIFY A NEW CFO, AIMING FOR AN ON-BOARDING IN Q1 OF 2021.RETIREMENT OF ITS CHIEF FINANCIAL OFFICER AT END 2020.  Full Article

Valneva Announces Positive Initial Results For Study Of Lyme Vaccine
Wednesday, 22 Jul 2020 

July 22 (Reuters) - VALVENA SE ::ANNOUNCES POSITIVE INITIAL RESULTS FOR PHASE 2 STUDY OF LYME DISEASE VACCINE CANDIDATE.PHASE 2 STUDY VLA15-201 MET ITS ENDPOINTS.VLA15 GENERALLY SAFE ACROSS ALL DOSE AND AGE GROUPS TESTED.NO RELATED SERIOUS ADVERSE EVENTS (SAES) ASSOCIATED WITH VLA15.ENCOURAGING IMMUNOGENICITY PROFILE CONFIRMED, INCLUDING OLDER ADULTS (50-65 YEARS).VALNEVA EXPECTS TO REPORT TOP-LINE RESULTS FOR SECOND PHASE 2 STUDY, VLA15-202, IN A FEW MONTHS.COMPARED TO PHASE 1, HIGHER DOSES USED IN THIS TRIAL ELICITED HIGHER ANTIBODY RESPONSES ACROSS ALL SEROTYPES.  Full Article

Bavarian Nordic And Valneva Announce Partnership
Thursday, 18 Jun 2020 

June 18 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC AND VALNEVA ANNOUNCE MARKETING AND DISTRIBUTION PARTNERSHIP.COMPANIES HAVE SIGNED A TERM SHEET OUTLINING A MUTUAL AGREEMENT, WHICH WILL CREATE SIGNIFICANT COMMERCIAL SYNERGIES AND A MARKET LEADERSHIP POSITION IN SPECIALTY VACCINE INDUSTRY.PARTNERSHIP AGREEMENT HAS NO MATERIAL SHORT TERM FINANCIAL IMPACT.WILL TRANSFER MARKETING AND DISTRIBUTION FOR RABIPUR/RABAVERT AND ENCEPUR FROM GSK FOR KEY MARKETS LATER THIS YEAR.VALNEVA TO ASSUME RESPONSIBILITY FOR MARKETING AND DISTRIBUTION OF VACCINES FOR RABIES AND TICK-BORNE ENCEPHALITIS IN SELECTED EUROPEAN COUNTRIES AND CANADA.VALNEVA TO ASSUME RESPONSIBILITY FOR MARKETING AND DISTRIBUTION OF VACCINES FOR RABIES AND TICK-BORNE ENCEPHALITIS STARTING IN H2 2020.  Full Article

Valneva: Hart-Scott-Rodino Clearance For Lyme Vaccine Collaboration With Pfizer
Monday, 8 Jun 2020 

June 8 (Reuters) - VALNEVA SE ::VALNEVA ANNOUNCES HART-SCOTT-RODINO CLEARANCE FOR LYME VACCINE COLLABORATION WITH PFIZER.AGREEMENT IS NOW EFFECTIVE AND VALNEVA WILL RECEIVE A $130 MILLION UPFRONT PAYMENT..ANTITRUST-RELATED CONDITION PRECEDENT FOR LYME VACCINE COLLABORATION AGREEMENT WITH PFIZER HAS BEEN MET.VALNEVA IS ELIGIBLE TO RECEIVE A TOTAL OF $308 MILLION CASH PAYMENTS.PAYMENTS CONSISTING OF $130 MILLION UPFRONT PAYMENT DESCRIBED ABOVE, $35 MILLION IN DEVELOPMENT MILESTONES AND $143 MILLION IN EARLY COMMERCIALIZATION MILESTONES.VALNEVA WILL FUND 30% OF ALL DEVELOPMENT COSTS THROUGH COMPLETION OF DEVELOPMENT PROGRAM.IN RETURN PFIZER WILL PAY VALNEVA TIERED ROYALTIES STARTING AT 19%.  Full Article

Valneva Confirms Repurchase Of About 18 Million Preferred Shares
Friday, 29 May 2020 

May 29 (Reuters) - VALNEVA SE ::VALNEVA CONFIRMS REPURCHASE OF PREFERRED SHARES IN ACCORDANCE WITH COMPANY'S ARTICLES.COMPANY ANNOUNCES IT WILL REPURCHASE ALL OF 17,836,719 PREFERRED SHARES AT THEIR NOMINAL VALUE OF ONE EURO CENT PER SHARE.HOLDERS DO NOT NEED TO TAKE ANY ACTION; PROCESS WILL BE IMPLEMENTED AUTOMATICALLY BY JUNE 10, 2020.IN ACCORDANCE WITH PARAGRAPH 5 IN SECTION 13.3 OF COMPANY'S ARTICLES, REPURCHASED SHARES WILL BE CANCELED AND COMPANY'S SHARE CAPITAL WILL BE REDUCED BY EUR 178,367.19.  Full Article

Valneva Q1 EBITDA Down At 2.4 Million Euros
Thursday, 7 May 2020 

May 7 (Reuters) - Valneva SE ::EBITDA OF €2.4 MILLION IN Q1 2020, LOWER THAN Q1 2019 (€8.2 MILLION) DUE TO INCREASED RESEARCH AND DEVELOPMENT INVESTMENTS.PRODUCT SALES REVENUE OF EUR 32.7 MILLION IN Q1 2020, SIMILAR TO Q1 2019 (EUR 32.8 MILLION).POSITIVE OPERATING CASH FLOW OF EUR 3.0 MILLION IN Q1 2020.STRONG CASH POSITION OF EUR 80.8 MILLION AT END OF MARCH 2020.LIMITED BUSINESS IMPACT OF COVID-19 CRISIS DURING Q1.TOTAL REVENUES NOW ESTIMATED TO BE BETWEEN EUR 95 MILLION AND EUR 135 MILLION IN 2020.PRODUCT SALES REVENUE GUIDANCE REVISED TO EUR 75 MILLION TO EUR 95 MILLION NOTING CONTINUING IMPACT OF COVID-19 PANDEMIC.EXPECTS IMPROVED NEGATIVE EBITDA OF EUR 10 MILLION TO EUR 30 MILLION IN 2020 (COMPARED TO PREVIOUS GUIDANCE OF UP TO EUR 50 MILLION NEGATIVE EBITDA) IN 2020.  Full Article

Valneva To Partner With Instituto Butantan On Single-Shot Chikungunya Vaccine
Tuesday, 5 May 2020 

May 5 (Reuters) - Valneva SE ::REG-VALNEVA TO PARTNER WITH INSTITUTO BUTANTAN ON SINGLE-SHOT CHIKUNGUNYA VACCINE FOR LOW- AND MIDDLE- INCOME COUNTRIES.DEFINITIVE AGREEMENTS ARE EXPECTED TO BE FINALIZED IN NEXT SIX MONTHS.COLLABORATION FALLS WITHIN FRAMEWORK OF $23.4 MILLION IN FUNDING VALNEVA RECEIVED FROM COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) IN JULY 2019.  Full Article

Valneva And Dynavax Announce Collaboration To Advance Vaccine Development For Covid-19
Thursday, 23 Apr 2020 

April 22 (Reuters) - Dynavax Technologies Corp ::VALNEVA AND DYNAVAX ANNOUNCE COLLABORATION TO ADVANCE VACCINE DEVELOPMENT FOR COVID-19.VALNEVA SE - DYNAVAX IS PROVIDING CPG 1018 TO SUPPORT DEVELOPMENT OF VALNEVA'S COVID-19 VACCINE CANDIDATE.VALNEVA SE - VALNEVA WILL SEEK GRANT FUNDING TO SUPPORT REQUIRED INVESTMENT FOR PROGRAM.VALNEVA SE - CO, DYNAVAX WILL WORK WITH REGULATORY AUTHORITIES TO ALIGN ON OPTIMAL STRATEGY TO EXECUTE AN EXPEDITED CLINICAL DEVELOPMENT PATH.VALNEVA SE - VALNEVA AND DYNAVAX WILL WORK WITH REGULATORY AUTHORITIES WITH GOAL TO INITIATE CLINICAL TRIALS BEFORE END OF 2020.  Full Article

Valneva Reports Positive End-Of-Phase 2 Chikungunya Meeting With The U.S. FDA
Wednesday, 25 Mar 2020 

March 25 (Reuters) - Valneva SE ::VALNEVA REPORTS POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA; SETS STAGE FOR PHASE 3 STUDY.STUDY INITIATION AS SOON AS COVID-19 SITUATION PERMITS, CURRENTLY ANTICIPATED FOR Q4 2020.PRIMARY ENDPOINT ANALYSIS IS EXPECTED SIX MONTHS THEREAFTER.FINAL ANALYSIS WILL BE CONDUCTED AT DAY 180 (SIX MONTHS AFTER IMMUNIZATION).TOTAL DURATION OF STUDY IS EXPECTED TO BE NINE MONTHS.  Full Article

Valneva Provides Update On Its Operations As COVID-19 Situation Evolves
Tuesday, 24 Mar 2020 

March 24 (Reuters) - VALNEVA SE ::PROVIDED AN UPDATE ON ITS OPERATIONS AS COVID-19 SITUATION EVOLVES.ON COVID-19: EXPECTS THAT ITS 2020 REVENUES MAY BE ADVERSELY AFFECTED.ON CORONAVIRUS: AS PROVIDER OF TWO TRAVEL VACCINES, ONE AGAINST JAPANESE ENCEPHALITIS AND ONE AGAINST CHOLERA/ETEC, COMPANY EXPECTS THAT ITS 2020 REVENUES MAY BE ADVERSELY AFFECTED.ON COVID-19: ESTIMATES THAT 2020 PRODUCT SALES REVENUES COULD BE IMPACTED BY BETWEEN EUR 20 MILLION AND EUR 40 MILLION.FIRST-QUARTER SALES 2020 WILL NOT BE MATERIALLY ADVERSELY AFFECTED AS IMPACT OF COVID-19 CRISIS DID NOT AFFECT ITS MAJOR MARKETS UNTIL MARCH.COMPANY IS WELL POSITIONED TO DEAL WITH CRISIS.IS ALSO WELL PLACED TO TAKE COST MANAGEMENT MEASURES IF REQUIRED AND HAS COMMENCED A REVIEW OF NON-MISSION CRITICAL PROJECTS AND EXPENSES.REDUCTION IN PRODUCT SALES REVENUE, OFFSET BY LIKELY DELAY IN CHIKUNGUNYA PHASE 3 INITIATION AND THEREFORE DELAY OF INITIAL PHASE 3 COSTS, MAY LEAD TO NEGATIVE EBITDA OF UP TO EUR 50 MILLION IN 2020 COMPARED TO EARLIER GUIDANCE OF NEGATIVE EBITDA OF UP TO EUR 35 MILLION.CASH POSITION AT END OF 2020 COULD BE IN RANGE OF EUR 35 MILLION TO EUR 40 MILLION.  Full Article

Valneva to supply up to 190 million doses of COVID-19 vaccine to UK

French vaccine maker Valneva said on Monday it would supply the UK with up to 190 million doses of its coronavirus vaccine candidate, VLA2001, over a five-year period.